Patents by Inventor Danielle Mitchell
Danielle Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939392Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: December 21, 2021Date of Patent: March 26, 2024Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20220363773Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: December 21, 2021Publication date: November 17, 2022Inventors: Gabriela HERNANDEZ-HOYOS, Elaine T. SEWELL, Catherine J. MCMAHAN, David BIENVENUE, John W. BLANKENSHIP, Danielle MITCHELL, Peter PAVLIK
-
Patent number: 11312786Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: GrantFiled: February 21, 2019Date of Patent: April 26, 2022Assignees: Aptevo Research and Development LLC, Alligator Bioscience ABInventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Patent number: 11242400Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: September 21, 2017Date of Patent: February 8, 2022Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20200223933Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: ApplicationFiled: July 20, 2018Publication date: July 16, 2020Inventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Patent number: 10676533Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: March 22, 2018Date of Patent: June 9, 2020Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20200165346Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: September 21, 2017Publication date: May 28, 2020Inventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20190382503Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: ApplicationFiled: February 21, 2019Publication date: December 19, 2019Inventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Patent number: 10239949Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: GrantFiled: July 20, 2018Date of Patent: March 26, 2019Assignees: Aptevo Research and Development, LLC, Alligator Bioscience ABInventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Publication number: 20190071513Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: ApplicationFiled: March 22, 2018Publication date: March 7, 2019Inventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Publication number: 20190016816Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.Type: ApplicationFiled: July 20, 2018Publication date: January 17, 2019Inventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
-
Publication number: 20180072137Abstract: A single, thick, durable, flexible, transparent plastic sheet, cut to a pre-selected pattern that replaces a vehicle's missing or damaged side or rear glass windows and is for temporary use or pleasure. Also referred to as a plastic window or sheet or a cosmetic window covering, this plastic sheet fits snugly within the seal of the vehicle's door window or rear window frames. Each plastic window sheet may be secured within the window seal/molding using a sturdy, elongated flat rod (also referred to as the “securing device”) made of a hard, thick plastic and may be inserted into a fold located at the top of each plastic sheet (this step is optional). The plastic sheets may be available with UV protection and/or in an assortment of color options, prints, and tints for privacy, style, fun and fashion. This inventive plastic window may also be used on the opposite window of the same vehicle making it reusable, recyclable and eco-friendly product.Type: ApplicationFiled: September 13, 2016Publication date: March 15, 2018Inventor: Pricess Danielle Mitchell
-
Publication number: 20160044146Abstract: Introducing a solar energy based technology that introduces mobile and electronic devices to energy and power by way solar integration. Solar panels will be positioned on the backside of the device's outer shell where it will also be embedded within the outer casing. The solar energy to the mobile terminal's power management system will function in one or more of the following modes: 1) allow usage of mobile devices (also known as “cellular” devices) with battery as a back-up energy source; 2) provide the ability to recharge a low or dead battery by way of the trickle charge effect when device is not in use; and/or 3) the use of a switch-mode-power-supply (SMPS) which will allow mobile device to be manually switched between energy usage using either solar/light power or a battery.Type: ApplicationFiled: July 1, 2015Publication date: February 11, 2016Inventor: Princess Danielle Mitchell